4 ?5 d7 V. b' n' t. p, C' H临床上有依维莫司联合EGFR TKI作为易/特耐药之后的方案的研究: & ~: p* ?3 |& v. v% kEverolimus and erlotinib as second- or third-line therapy in patients with advanced non-small-cell lung cancer.7 `( B6 x+ \/ w% ?- Y http://www.ncbi.nlm.nih.gov/pubmed/22968184 9 s' n9 `6 h ~( P6 C: ~+ m% P% E7 w9 N+ }. m8 D; T! V
依维莫司联合吉非替尼抑制非小细胞肺癌细胞系的效果和作用机制. }. ^) v: e$ U) Z# n2 J http://d.wanfangdata.com.cn/Thesis_Y1770447.aspx